Applied Genetics Technology Corporation: Strong Science And Clinical Efficacy [Seeking Alpha]
MeiraGTx Holdings plc - Ordinary Shares (MGTX)
Company Research
Source: Seeking Alpha
Applied Genetics Technology Corporation: Strong Science And Clinical Efficacy Summary AGTC is among the most undervalued stocks in biotech with the potential for a 1,000% return in the next several months. AGTC's X-linked retinitis pigmentosa data appear to be at least as good as competitor Biogen/Nightstar. AGTC has a broad clinical and preclinical pipeline. Have you seen the explosion in biotech stocks of late? There may be another in the works. Applied Genetics nology Corporation ( AGTC's Lead Program Is for a Sizable Market AGTC is developing gene therapies for rare ophthalmologic disorders. Leading the pipeline is X-linked retinitis pigmentosa (XLRP), a disorder affecting males which causes night blindness in its early stages and loss of central vision in its later stages. XLRP is caused by mutations in the retinitis pigmentosa GTPase regulator RPGR gene and is the most common form of recessive retinitis pigmentosa (RP). RP is a heterogeneous disorder affecting one in 3,000 to 4,
Show less
Read more
Impact Snapshot
Event Time:
MGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTX alerts
High impacting MeiraGTx Holdings plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MGTX
News
- Latest Published 5 Rare Eye Diseases Market Reports by DelveInsight: Retinitis Pigmentosa, Stargardt Disease, Ocular Melanoma, Uveitis, and Neurotrophic Keratitis [Yahoo! Finance]Yahoo! Finance
- Investors in MeiraGTx Holdings (NASDAQ:MGTX) have unfortunately lost 71% over the last five years [Yahoo! Finance]Yahoo! Finance
- MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced XerostomiaGlobeNewswire
- Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive DirectorsPR Newswire
- MeiraGTx Holdings plc (NASDAQ: MGTX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $36.00 price target on the stock.MarketBeat
MGTX
Earnings
- 11/13/24 - Miss
MGTX
Sec Filings
- 12/9/24 - Form 8-K
- 11/13/24 - Form 10-Q
- 11/13/24 - Form 8-K
- MGTX's page on the SEC website